Netherlands · Delayed Price · Currency is EUR Corbion Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 results showed lower sales and margins versus a strong prior year, but momentum is building with robust demand in core segments and cost reductions set to drive improvement from Q2. Full-year guidance is reaffirmed, with strong cash generation and margin recovery expected.
Fiscal Year 2025
-
Delivered strong organic growth, improved profitability, and robust free cash flow in 2025, with EPS up 63% and a proposed EUR 1 per share dividend. 2026 guidance targets 3%-6% organic sales growth, 17% EBITDA margin, and continued portfolio focus.
-
Advance 2025 goals were met, with margin expansion and portfolio transformation. Bright 2030 targets 3%-6% annual sales growth, 18% EBITDA margin by 2028, and EUR 270 million free cash flow, focusing on natural preservation, nutrition, and biomedical polymers, while exiting non-core areas.
-
Organic sales grew 2.9% to €645M in H1 2025, with adjusted EBITDA up nearly 24% and margin rising 300 bps to 16.5%. Guidance for FY 2025 is reaffirmed, targeting 2–6% volume growth and over 25% EBITDA growth, supported by operational efficiencies and strong demand in key segments.
-
Q1 2025 saw 7.9% organic sales growth and a 53.9% rise in adjusted EBITDA, with strong results across both business units. Guidance for over 25% adjusted EBITDA growth in 2025 is maintained, supported by margin improvements and disciplined investment.
Fiscal Year 2024
-
Met upgraded 2024 targets with 2.2% organic sales growth, 23.3% organic Adjusted EBITDA growth, and EUR 98.3 million free cash flow. Health and nutrition led performance, while cost-saving and restructuring supported margins. 2025 guidance targets continued strong growth and disciplined capital allocation.
-
Accelerated organic sales and volume growth drove strong Q3 and year-to-date results, prompting upgrades to full-year guidance for volume, EBITDA, and free cash flow. Segment performance was robust, though PLA JV margins remain under pressure due to pricing in Asia.
-
Strong H1 2024 results featured robust volume mix growth, improved EBITDA margins, and positive free cash flow, with health and nutrition and PLA segments leading performance. Guidance for 2024 and 2025 remains confident, supported by strategic investments and restructuring.